𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type

✍ Scribed by Linda M. S. Resar; Peter C. Phillips; Michael B. Kastan; Brigid G. Leventhal; Paul W. Bowman; Curt I. Civin

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
730 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Background. Two adolescents with acute B-cell leukemia (Burkitt leukemia) had acute severe neurotoxicity after treatment with intrathecal (IT) cytosine arabinoside (AraC) at a dose of 50 mg/day for three consecutive days.

A 16-year-old boy had a rapidly ascending myelopathy and encephalopathy 20 hours after receiving the third dose of IT AraC. He remained quadriplegic and required ventilatory assistance for 10 months until his death from progressive tumor. .4 12-year-old girl had acute encephalopathy, seizures, and focal neuroimaging abnormalities in the cerebellum and brain stem within 32 hours of the third AraC dose and 8 hours after IT methotrexate (MTX, 1 2 mg). Her clinical neurologic deficits resolved during the ensuing month. Patient 1 represents the first report to the authors' knowledge of acute severe neurotoxicity after AraC administered as the only IT drug. In Patient 2, IT AraC neurotoxicity may have been potentiated by the single dose of MTX.

IT AraC administered for 3 or more consecutive days may lead to profound neurologic dysfunction and require discontinuation of therapy. Cancer Results.

Conclusion.

πŸ“œ SIMILAR VOLUMES

Intracellular retention of cytosine arab
Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia
✍ Boos, Joachim; HohenlΓΆchter, Barbara; Schulze-Westhoff, Petra; Schiller, Meinhar πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 764 KB

The importance of the cellular pharmacokinetics of cytarabine triphosphate (ara-CTP) with regard to therapeutic efficacy is well established. In vitro and in vivo monitoring of pharmacokinetic parameters of leukemic blast cells were initiated in order to contribute to the pharmacological basis of op

Relapse in childhood acute lymphoblastic
Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: Failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP)
✍ Sallan, Stephen E. ;Hitchcock-Bryan, Suzanne πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 425 KB

## Abstract Although the majority of children with acute lymphoblastic leukemia (ALL) can electively stop treatment after 21/2–5 years of continuous disease‐free remission, 20–25% of those patients relapse after discontinuation of therapy. We treated 15 patients whose disease recurred after stoppin

Effective preventive central nervous sys
Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia : The ISRAEL National Study report
✍ Batia Stark; Rivka Sharon; Gideon Rechavi; Dina Attias; Ami Ballin; Gabriel Civi πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

BACKGROUND. Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies. Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups. In